Synmosa Biopharma (4114) reported revenue of NT$766.6 million for Oct 2026, +41.2% year on year and +2.6% from the previous month. Revenue for Jan–Oct 2026 was NT$6.61 billion (+28.5% year on year).
Year-on-year revenue growth: 8 months in a row. →
In Oct 2026, it ranked No. 7 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$766.6 million | +41.2% | +2.6% |
| Sep 2026 | NT$747 million | +38.7% | -1.0% |
| Aug 2026 | NT$754.3 million | +49.9% | -4.7% |
| Jul 2026 | NT$791.7 million | +59.8% | +5.4% |
| Jun 2026 | NT$750.9 million | +30.7% | +25.0% |
| May 2026 | NT$600.8 million | +12.9% | +5.3% |
| Apr 2026 | NT$570.4 million | +13.5% | +1.4% |
| Mar 2026 | NT$562.6 million | +17.3% | +30.8% |
| Feb 2026 | NT$430.3 million | -7.8% | -32.2% |
| Jan 2026 | NT$634.9 million | +25.4% | +16.8% |
| Dec 2025 | NT$543.7 million | +4.3% | +8.2% |
| Nov 2025 | NT$502.6 million | +0.9% | -7.4% |
| Oct 2025 | NT$543 million | +9.2% | +0.8% |
| Sep 2025 | NT$538.6 million | +21.7% | +7.0% |
| Aug 2025 | NT$503.2 million | +2.0% | +1.6% |
| Jul 2025 | NT$495.5 million | +1.3% | -13.8% |
| Jun 2025 | NT$574.6 million | +51.5% | +8.0% |
| May 2025 | NT$532.1 million | +10.2% | +5.9% |
| Apr 2025 | NT$502.5 million | +6.6% | +4.7% |
| Mar 2025 | NT$479.7 million | +14.9% | +2.8% |
| Feb 2025 | NT$466.7 million | +62.3% | -7.8% |
| Jan 2025 | NT$506.2 million | -12.9% | -2.9% |
| Dec 2024 | NT$521.1 million | +20.1% | +4.6% |
| Nov 2024 | NT$498.1 million | +12.2% | +0.2% |
| Oct 2024 | NT$497.2 million | +10.1% | +12.4% |
Jan–Oct 2026 cumulative: NT$6.61 billion (+28.5% YoY)
Other Biotech & Medical companies
Compare with peers: Synmosa Biopharma vs PEC / Synmosa Biopharma vs Lotus Pharm / Synmosa Biopharma vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Y.S.H. | NT$749.4 million | +4.4% |
| GKB | NT$748.3 million | -30.8% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16